

SUPPORTING INFORMATION

Ammonium Ylides for the Diastereoselective Synthesis of Glycidic Amides

Mario Waser,* Richard Herchl and Norbert Müller

*Institute of Organic Chemistry, Johannes Kepler University Linz, Altenbergerstraße 69, 4040 Linz,
Austria. Fax: +43 732 2468 8747; Tel: +43 732 2468 8748;*


E-mail: Mario.waser@jku.at

1. General Information:	2
2. Syntheses of DABCO-Ammonium Salts 2, 4, 6, and 8:	2
3. Syntheses of Glycidic Amides:	4
4. NMR Spectra of the Novel Ammonium Salts 2, 4, 6, and 8:	8
5. Representative NMR Spectra for <i>trans</i> -Epoxide Products:	12

1. General Information:


Melting points were measured on a Kofler melting point microscope (Reichert, Vienna). ^1H - and ^{13}C -NMR spectra were recorded on a Bruker Avance DRX 500 MHz spectrometer using a TXI cryoprobe with z -gradient coil and on a Bruker Avance DPX 200 MHz spectrometer. Typical resolutions and chemical shift precisions were +/- 1 Hz for ^1H and +/- 0.8 Hz for ^{13}C . All NMR spectra were referenced on the solvent peak. High resolution mass spectra were obtained using an Agilent 6520 Q-TOF mass spectrometer with an ESI source and an Agilent G1607A coaxial sprayer. All analyses were made in the positive ionization mode. Purine (exact mass for $[M+H]^+ = 121.050873$) and 1,2,3,4,5,6-hexakis(2,2,3,3-tetrafluoropropoxy)-1,3,5,2,4,6-triazatriphosphinane (exact mass for $[M+H]^+ = 922.009798$) were used for internal mass calibration. IR spectra were recorded on a Shimadzu IR Affinity-1 fourier transform infrared spectrometer. All chemicals were purchased from commercial suppliers and used without further purification unless otherwise stated. All reactions were performed under an Ar-atmosphere.

2. Syntheses of DABCO-Ammonium Salts 2, 4, 6, and 8:




General Procedure: One equivalent of DABCO was added to a solution of one equivalent of the α -bromo amide in THF (15 mL / g amide) and stirred for 24 h at room temperature. The resulting suspension was centrifuged, the solid washed 3 times with EtOAc and dried in vacuo to give the product in sufficient purity for the epoxide formation reaction.

Ammonium Salt 2. Prepared from 2-bromo-*N,N*-diethylacetamide¹ (4.06 g, 20.9 mmol) in




4.07 (t, *J* = 7.3 Hz, 6H), 4.73 (s, 2H) ppm; ¹³C NMR (125 MHz, δ, CDCl₃, 298 K): 12.8 (CH₃-), 14.4 (CH₃-), 41.0 (-CH₂-), 42.1 (-CH₂-), 45.4 (-NCH₂-), 53.0 (-NCH₂-) 61.2 (-CH₂CO-), 162.2 (-CO-) ppm; IR (film): $\bar{\nu}$ = 3532, 3406, 2972, 2941, 2893, 1632, 1489, 1479, 1470, 1431, 1397, 1368, 1310, 1265, 1215, 1109, 1072, 1053, 961, 893, 839 cm⁻¹; HRMS (ESI): *m/z* calcd for C₁₂H₂₄N₃O⁺: 226.1919 [M⁺]; found: 226.1922.

Ammonium Salt 4. Prepared from 2-bromo-*N,N*-dibenzylacetamide² (1.56 g, 4.92 mmol) in



NMR (50 MHz, δ, CDCl₃, 298 K): 45.3 (-NCH₂-), 48.8 (-CH₂-Ar), 50.7 (-CH₂-Ar), 53.0 (-NCH₂-), 61.7 (-CH₂CO-), 127.9 (Ar-C), 128.0 (Ar-C), 128.1 (Ar-C), 128.3 (Ar-C), 129.0 (Ar-C), 129.3 (Ar-C), 135.2 (Ar-C_{quat}), 135.8 (Ar-C_{quat}), 164.1 (-CO-) ppm; IR (film): $\bar{\nu}$ = 3399, 2974, 2943, 2887, 1655, 1493, 1481, 1449, 1418, 1397, 1364, 1234, 1117, 1057, 1026, 994, 841, 752, 739, 725, 694 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₂H₂₈N₃O⁺: 350.2232 [M⁺]; found: 350.2234.

Ammonium Salt 6. Prepared from *N*-benzyl-2-bromoacetamide³ (4.50 g, 19.8 mmol) in 62%




2H), 9.42 (bs, 1H) ppm; ¹³C NMR (125 MHz, δ, CDCl₃, 298 K): 43.6 (-CH₂-Ar), 45.4 (-NCH₂-), 53.5 (-NCH₂-), 63.2 (-CH₂CO-), 127.6 (Ar-C), 128.1 (Ar-C), 128.8 (Ar-C), 137.6 (Ar-C_{quat}), 162.8 (-CO-) ppm; IR (film): $\bar{\nu}$ = 3173, 3035, 2962, 2951, 2912, 2884, 1663, 1553, 1495, 1452, 1431, 1367, 1331, 1315, 1294, 1223, 1103, 1055, 1026, 993, 841, 729, 708, 607 cm⁻¹; HRMS (ESI): *m/z* calcd for C₁₅H₂₂N₃O⁺: 260.1763 [M⁺]; found: 260.1757.

¹ T. Hama, X. Liu, D. A. Culkin and J. F. Hartwig, *J. Am. Chem. Soc.*, 2003, **125**, 11176.

² P. M. P. Gois and C. A. M. Afonso, *Eur. J. Org. Chem.*, 2003, 3798.


³ A. M. R. Smith, H. S. Rzepa, A. J. P. White, D. Billen and K. K. (M.) Hii, *J. Org. Chem.*, 2010, **75**, 3085.

Ammonium Salt 8. Prepared from 2-bromo-1-(piperidin-1-yl)ethanone⁴ (1.10 g, 5.36 mmol)



in 70% (1.19 g, 3.75 mmol). Hygroscopic white solid. M.p.: 164-167 °C; ¹H NMR (500 MHz, δ , CDCl₃, 298 K): 1.27-1.37 (m, 6H), 2.93 (m, 6H), 3.15-3.34 (m, 4H), 3.83 (m, 6H), 4.65 (s, 2H) ppm; ¹³C NMR (125 MHz, δ , CDCl₃, 298 K): 23.8 (-CH₂-), 25.1 (-CH₂-), 26.0 (-CH₂-), 42.6 (-CON-CH₂-), 45.2 (-NCH₂-), 46.1 (-CON-CH₂-), 52.4 (-NCH₂-), 60.9 (-CH₂CO-), 161.1 (-CO-) ppm; IR (film): $\bar{\nu}$ = 2930, 2856, 1638, 1472, 1435, 1402, 1346, 1323, 1248, 1229, 1061, 1017, 990, 848, 787, 745 cm⁻¹; HRMS (ESI): *m/z* calcd for C₁₃H₂₄N₃O⁺: 238.1919 [M⁺]; found: 238.1925.

3. Syntheses of Glycidic Amides:




General procedure for the preparation of epoxides using homogeneous or liquid/solid conditions (Table 1, entries 1-8): 1.2 equiv. of *t*-BuOK (or other base) were added to a mixture of ammonium salt **2** in THF (or other solvent) at 0 °C and stirred for 5 min. After addition of the indicated amount of aldehyde **1** the mixture was stirred at 0 °C for 1 h followed by stirring at 25 °C for 23 h. After extraction with EtOAc and NH₄Cl the organic layer was washed with brine, dried over Na₂SO₄ and evaporated to dryness. Column chromatography (silica gel, hexanes/EtOAc = 7:3) gave **3** in the reported yields.

Optimized procedure for the preparation of epoxides under biphasic conditions (using 2 equiv. of aldehyde): A vigorously stirred solution of ammonium salt (2 mmol) in CH₂Cl₂ (30 mL) was cooled to 0 °C, followed by addition of 50% NaOH (15 mL). After 5 min the aldehyde (4 mmol) was added in one portion. The biphasic mixture was warmed to 25 °C over 1 h and vigorously stirred for 23 h. After extraction with EtOAc the organic layer was washed with brine, dried over Na₂SO₄ and evaporated to dryness. Column chromatography (silica gel, hexanes/EtOAc = 7:3) gave the glycidic amides in the reported yields (For copies of NMR spectra of 2 representative *trans*-epoxide products see chapter 5).


⁴ B. C. Gorske, B. L. Bastian, G. D. Geske, and H. E. Blackwell, *J. Am. Chem. Soc.*, 2007, **129**, 8928.

***trans*-*N,N*-diethyl-3-phenyloxirane-2-carboxamide (3).** Obtained in 67% using the biphasic




procedure as a white to yellow solid. Analytical data are in full accordance with those reported in literature.⁵ ¹H NMR (500 MHz, δ , CDCl₃, 298 K): 1.16 (t, J = 7.3 Hz, 3H), 1.20 (t, J = 7.3 Hz, 3H), 3.40-3.51 (m, 4H), 3.58 (d, J = 1.4 Hz, 1H), 4.09 (d, J = 1.4 Hz, 1H), 7.32-7.39 (m, 5H) ppm; ¹³C NMR (125 MHz, δ , CDCl₃, 298 K): 13.1, 15.0, 41.0, 41.6, 57.3, 57.7, 125.8, 128.6, 128.7, 135.9, 165.8 ppm; HRMS (ESI): m/z calcd for C₁₃H₁₇NO₂: 220.1332 [M+H]⁺; found: 220.1329.

***trans*-*N,N*-dibenzyl-3-phenyloxirane-2-carboxamide (5).** Obtained in 72% using the



biphasic procedure as a white to yellow solid. Analytical data are in full accordance with those reported in literature.⁶ ¹H NMR (500 MHz, δ , CDCl₃, 298 K): 3.70 (d, J = 1.2 Hz, 1H), 4.14 (d, J = 1.2 Hz, 1H), 4.55 (s, 2H), 4.69 (d, J = 4.8 Hz, 2H), 7.15-7.41 (m, 15H) ppm; ¹³C NMR (125 MHz, δ , CDCl₃, 298 K): 48.8, 49.4, 57.5, 58.2, 125.8, 126.7, 127.8, 128.0, 128.4, 128.6, 128.7, 128.8, 129.2, 135.4, 135.9, 136.5, 167.3 ppm; HRMS (ESI): m/z calcd for C₂₃H₂₁NO₂: 344.1645 [M+H]⁺; found: 344.1644.

***trans*-*N*-benzyl-3-phenyloxirane-2-carboxamide (7).** Obtained in 24% using the biphasic




procedure as a white solid. Analytical data are in full accordance with those reported in literature.⁷ ¹H NMR (500 MHz, δ , CDCl₃, 298 K): 3.58 (d, J = 1.2 Hz, 1H), 3.90 (d, J = 1.2 Hz, 1H), 4.49 (m, 2H), 6.57 (bs, 1H), 7.26-7.36 (m, 10H) ppm; ¹³C NMR (125 MHz, δ , CDCl₃, 298 K): 43.0, 59.1, 59.2, 125.9, 127.8, 127.9, 128.8, 128.9, 129.2, 134.9, 137.6, 167.4 ppm; HRMS (ESI): m/z calcd for C₁₆H₁₅NO₂: 276.0995 [M+Na]⁺; found: 276.0997.

⁵ Y.-G. Zhou, X.-L. Hou, L.-X. Dai, L.-J. Xia and M.-H. Tang, *J. Chem. Soc., Perkin Trans. 1*, 1999, 77.

⁶ O. Meth-Cohn, C. Moore, and H. C. Taljaard, *J. Chem. Soc., Perkin Trans. 1*, 1988, 2663.


⁷ T. Nemoto, T. Ohshima and M. Shibasaki, *J. Am. Chem. Soc.*, 2001, **123**, 9474.

***trans*-3-(3-phenyloxiran-2-yl)(piperidin-1-yl)methanone (9).** Obtained in 58% using the




biphasic procedure as a yellowish oil. Analytical data are in full accordance with those reported in literature.⁸ ¹H NMR (500 MHz, δ , CDCl₃, 298 K): 1.57-1.67 (m, 6H), 3.46-3.65 (m, 4H), 3.61 (d, J = 1.9 Hz, 1H), 4.05 (d, J = 1.9 Hz, 1H), 7.26-7.38 (m, 5H) ppm; ¹³C NMR (125 MHz, δ , CDCl₃, 298 K): 24.5, 25.5, 26.6, 43.4, 46.1, 57.6, 57.7, 125.7, 128.7, 128.8, 135.9, 164.9 ppm; HRMS (ESI): m/z calcd for C₁₄H₁₇NO₂: 232.1332 [M+H]⁺; found: 232.1330.

***trans*-*N,N*-diethyl-3-(*p*-tolyl)oxirane-2-carboxamide (11).** Obtained in 68% using the



biphasic procedure white to yellow solid. Analytical data are in full accordance with those reported in literature.⁵ ¹H NMR (500 MHz, δ , CDCl₃, 298 K): 1.15 (t, J = 7.1 Hz, 3H), 1.19 (t, J = 7.1 Hz, 3H), 2.34 (s, 3H), 3.38-3.49 (m, 4H), 3.57 (d, J = 1.7 Hz, 1H), 4.03 (d, J = 1.7 Hz, 1H), 7.16 (d, J = 8.2 Hz, 2H), 7.20 (d, J = 8.2 Hz, 2H) ppm; ¹³C NMR (125 MHz, δ , CDCl₃, 298 K): 13.0, 15.0, 21.3, 40.9, 41.5, 57.2, 57.7, 125.7, 129.4, 132.8, 138.7, 165.9 ppm; HRMS (ESI): m/z calcd for C₁₄H₁₉NO₂: 234.1489 [M+H]⁺; found: 234.1494.


***trans*-3-(4-chlorophenyl)-*N,N*-diethyloxirane-2-carboxamide (13).** Obtained in 72% using



the biphasic procedure as a white solid. Analytical data are in full accordance with those reported in literature.⁵ ¹H NMR (500 MHz, δ , CDCl₃, 298 K): 1.16 (t, J = 7.2 Hz, 3H), 1.20 (t, J = 7.2 Hz, 3H), 3.38-3.48 (m, 4H), 3.53 (d, J = 1.3 Hz, 1H), 4.07 (d, J = 1.3 Hz, 1H), 7.25 (d, J = 8.4 Hz, 2H), 7.33 (d, J = 8.4 Hz, 2H) ppm; ¹³C NMR (125 MHz, δ , CDCl₃, 298 K): 12.5, 14.5, 40.5, 41.1, 56.5, 56.7, 126.5, 128.4, 133.9, 134.1, 164.9 ppm; HRMS (ESI): m/z calcd for C₁₃H₁₆ClNO₂: 276.0762 [M+Na]⁺; found: 276.0762.

⁸ T. Satoh, T. Shimura, and K. Sakai, *Heterocycles*, 2003, **59**, 137.


***trans*-*N,N*-diethyl-3-(4-methoxyphenyl)oxirane-2-carboxamide (15).** Obtained in 47%



using the biphasic procedure at 25 °C as a bright yellow solid. Analytical data are in full accordance with those reported in literature.⁹ ¹H NMR (200 MHz, δ , CDCl₃, 298 K): 1.11-1.23 (m, 6H),

3.37-3.52 (m, 4H), 3.58 (d, J = 1.8 Hz, 1H), 3.80 (s, 3H), 4.02 (d, J = 1.8 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 7.23 (d, J = 8.8 Hz, 2H) ppm; ¹³C NMR (50 MHz, δ , CDCl₃, 298 K): 12.6, 14.8, 40.8, 41.4, 55.2, 57.0, 57.5, 114.1, 127.0, 127.7, 160.0, 165.8 ppm; HRMS (ESI): m/z calcd for C₁₄H₁₉NO₃: 272.1257 [M+Na]⁺; found: 272.1251.


***trans*-*N,N*-diethyl-3-(4-dimethylaminophenyl)oxirane-2-carboxamide (17).** ¹H NMR of



the crude product showed less than 20% of **17** besides unreacted starting material **16**. The product decomposed during column chromatography. ¹H NMR and HRMS of the crude product were

consistent with formation of the *trans*-epoxide: ¹H NMR (200 MHz, δ , CDCl₃, 298 K): 1.18 (m, 6H), 2.89 (s, 6 H), 3.37 (m, 4H), 3.58 (d, J = 1.7 Hz, 1H), 3.92 (d, J = 1.7 Hz, 1H), 6.61 (d, J = 8.5 Hz, 2H), 7.13 (d, J = 8.5 Hz, 2H) ppm; HRMS (ESI): m/z calcd for C₁₅H₂₂N₂O₂: 263.1754 [M+Na]⁺; found: 263.1756.

***trans*-*N,N*-diethyl-3-(4-nitrophenyl)oxirane-2-carboxamide (19).** ¹H NMR of the crude







product showed less than 10% of **19** and the corresponding Cannizzaro disproportionation products. ¹H NMR signals of the *trans*-oxirane ring are in accordance with literature.⁵ The formation of the



product was also evidenced by HRMS. HRMS (ESI): m/z calcd for C₁₃H₁₆N₂O₄: 287.1002 [M+Na]⁺; found: 287.1002.



⁹ R. Imashiro and M. Seki, *J. Org. Chem.*, 2004, **69**, 4216.

4. NMR Spectra of the Novel Ammonium Salts 2, 4, 6, and 8:














5. Representative NMR Spectra for *trans*-Epoxide Products:





9